We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn more.
Human Noggin (h Noggin, NOG) is a secreted homodimeric glycoprotein and is best known for inducing the development of neural tissue and inhibiting bone morphogenetic proteins (BMPs) such as BMP-4 (1,2). h Noggin inhibits BMPs by binding to BMP epitopes required for binding their Type I and Type II receptors, thus mediating a pathway that controls processes such as the establishment of the embryonic dorsal–ventral axis, induction of neural tissue, formation of joints in the skeletal system and neurogenesis in the adult brain (3,4).
Human Noggin has also proven to be useful in the culturing of human embryonic stem cells (hESC). The addition of human Noggin to hESC culture in unconditioned media synergizes with basic fibroblast growth factor (bFGF) and inhibits hBMP4 activity, thus allowing the hESCs proliferation while maintaining their undifferentiated state (4,5). In preclinical models, hNoggin has a high expression after induction of spinal cord injury and may play an important neuroprotective role in spinal cord injuries (6).
Product images on the website are not representative of actual product, including, but not limited to differences in cap color, tube type, or label format.


Figure 1. Western Blot image showing detection of rh Noggin bands


Figure 2. rh Noggin inhibits the alkaline phosphatase activity induced by BMP-4 in ATDC-5 cells


Figure 3. rh Noggin inhibits the alkaline phosphatase activity induced by BMP-4 in ATDC-5 cells
Centrifuge vial before opening. Suspend the product by gently pipetting the above recommended solution down the sides of the vial. DO NOT VORTEX. Allow several minutes for complete reconstitution. For prolonged storage, dilute to working aliquots in a 0.1% BSA solution, store at -80°C and avoid repeat freeze thaws.
| Alternate Names | NOG, h NOG |
| Accession Number | Q13253 |
| Source | CHO cells |
| Predicted Molecular Mass | Homodimer, 23 kDa (205 aa) |
| AA Sequence | QHYLHIRPAP SDNLPLVDLI EHPDPIFDPK EKDLNETLLR SLLGGHYDPG FMATSPPEDR PGGGGGAAGG AEDLAELDQL LRQRPSGAMP SEIKGLEFSE GLAQGKKQRL SKKLRRKLQM WLWSQTFCPV LYAWNDLGSR FWPRYVKVGS CFSKRSCSVP EGMVCKPSKS VHLTVLRWRC QRRGGQRCGW IPIQYPIISE CKCSC |
| Formulation | Lyophilized from a 0.2 µm filtered solution containing 10 mM NaP, 30 mM NaCl, pH 7.0 |
| Product Reconstitution | Sterile water at 0.1 mg/mL |
| Country of Origin | USA |
| Specification* | Method of Determination | Acceptance Criteria |
| Purity | Reducing and Non-Reducing SDS PAGE | ≥ 95% |
| Endotoxin | Kinetic LAL (50% confidence) | ≤ 0.1 EU/µg |
| Biological Activity (ED50) | Inhibition of BMP-4 induced alkaline phosphatase production by ATDC-5 cells | ≤ 3 ng/mL; 3.3 x 105 units/mg |
*Lot-specific values for the above specifications are supplied with each product on its corresponding COA. The values provided here are minimum expected values to pass internal requirements.
References: